CSPC Pharmaceutical Group's stock plummeted 5.11% during Tuesday's intraday trading session, following the disclosure of weak quarterly results from its subsidiary, CSPC Innovation Pharmaceutical.
The subsidiary reported a sharp 248.88% year-over-year widening in its first-quarter net loss attributable to shareholders, despite a 40.82% increase in revenue. After adjusting for non-recurring items, the net loss deepened to RMB 111 million, a 262.55% decline from the previous year. The significant divergence between revenue growth and profitability was primarily driven by a 56.88% surge in administrative expenses and a 13.64% increase in research and development spending, indicating heightened costs without corresponding profit improvement.
On a separate development, the group recently received U.S. Food and Drug Administration approval to initiate clinical trials for SYH2095, a novel highly selective KAT6 inhibitor co-developed for oncology, which may support its long-term pipeline expansion internationally.
Comments